Plan A Okklusjons- og reverseringssystem gjennomførbarhetsstudie
Prospektiv, Multicenter, Enarm, Åpen merke, Intervensjonell klinisk studie som undersøker sikkerheten og effektiviteten til Plan A mannlig prevensjonssystem.
Prospective, multicenter, single-arm, open label, interventional clinical trial investigating the safety and effectiveness of the Plan A Male Contraceptive System to occlude the vas deferens to block the passage of sperm and then be reversed to subsequently allow the passage of sperm through the vas deferens.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Prospective, multicenter, single-arm, open label, interventional clinical trial investigating the safety and effectiveness of the Plan A Male Contraceptive System to occlude the vas deferens to block the passage of sperm and then be reversed to subsequently allow the passage of sperm through the vas deferens. 40 men (all sites) will be enrolled and treated with Plan A occlusion (Vasalgel®) using DLAD (Delivery Lumen Access Device). The study will enroll into two groups. Group 1 will include 30 subjects that will be followed for up for a maximum of 6 months post occlusion procedure, or until they achieve azoospermia at which point they will be offered a vasectomy procedure. Group 2 will recruit ten subjects who will be followed for up for a maximum of 6 months post occlusion procedure, or until they achieve azoospermia at which point they will have the reversal procedure using the Plan A RD (Reversal Device). This group will be followed for up to another 3 months maximum, or until baseline semen levels are achieved at which point they will be offered a vasectomy procedure. Ten men reaching azoospermia after their occlusion procedure will be allocated to Group 2 and will go on to have the reversal procedure.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Darlene Walley R Chief Executive Officer, PhD
- Telefonnummer: 1-415-407-5229
- E-post: darlene.walley@nextlifesciences.org
Studiesteder
-
-
Victoria
-
Maribyrnong, Victoria, Australia, 3032
- Rekruttering
- Western Urology
-
Ta kontakt med:
- Homi Zargar, MD
- Telefonnummer: +1 61 300 927 427
- E-post: pa@homizargar.com.au
-
St Kilda, Victoria, Australia, 3182
- Rekruttering
- Dr. Snip
-
Ta kontakt med:
- Sarah Demediuk, MD
- Telefonnummer: 1300 377 647
- E-post: sarah@drsnip.au
-
-
-
-
Ontario
-
Hawkesbury, Ontario, Canada, K6A 1A8
- Har ikke rekruttert ennå
- Clinique de Vasectomie
-
Ta kontakt med:
- Jean Philippe-Bercier, MD
- Telefonnummer: 613-762-0997
- E-post: jeanphilippebercier@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male subject who is seeking and suitable to undergo a vasectomy as a long-term form of contraception
- Male subject who has voluntarily signed and dated the Institutional Review Board (IRB)/Ethics Committee (EC) approved informed consent form (ICF) for this study prior to initiation of any screening or study specific procedures
- 25 to 65 years of age at the time of consent
- Body Mass Index (BMI) <31 kg/m2
- Good health for undergoing a vasectomy as confirmed by medical history, physical examination and clinical laboratory tests of blood and urine at the time of screening
- Normal semen analysis defined by the WHO Laboratory Manual for the Examination and Processing of Human Semen (6th Edition), based on the average of two semen samples ≥2 days and ≤7 days apart
- In the opinion of the Investigator, subject is suitable to undergo a vasectomy as a form of long-term contraception
- Agreement to use an effective method of contraception during the entire clinical trial until the planned vasectomy
- Lives in close proximity to the trial site to enable provision of fresh semen samples unless the subject agrees to provide semen samples at the trial site or laboratory
Exclusion Criteria:
- (On exam, has any of the following); one or both vasa not present, abnormal scrotum, large varicocele, hydrocele, filariasis or elephantiasis of scrotum, or intrascrotal mass that would make the subject not suitable for the study.
- Prior testicular surgery, testicular injury or prior vasectomy with vasovasostomy (vasectomy reversal)
- Recurrent pain with ejaculations
- Has known allergic reaction to sulfur-containing products or has had a prior severe allergic response to injectable or implantable devices
- Has local genital infections such as balanitis, scrotal skin infection, epididymitis, or orchitis, or tender (inflamed) tip of the penis, but may be enrolled after resolution of an acute infection
- History of prostatitis or benign prostatic hypertrophy requiring treatment
- Has undergone prior chemotherapy
- Has known current coagulopathy or other bleeding disorders
- Currently taking or planning to take any type of systemic medication which could affect sperm count or ejaculation (e.g., anabolic steroids, chemotherapy, alpha blocker)
- Subjects with cystic fibrosis
- Subjects with a history of inguinal hernia repair
- Vulnerable subjects (e.g., subjects with cognitive challenges, incarcerated, etc.)
- Currently participating in another study involving an investigational device or drug (or has participated in a study within the last 30 days prior to screening).
- Any site staff member with delegated study responsibilities or a family member of a site staff member with delegated study responsibilities
- In the opinion of the Investigator, there are issues or concerns that may compromise the safety of the subject or confound the reliability of compliance and information acquired in this study
- Has any condition that, in the opinion of the Investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Group 1: Occlusion Procedure
This will be Group 1. Group1 will have the occlusion procedure but will not have the reversal procedure. |
The occlusion system comprised of the Delivery Lumen Access Device and Vasalgel. |
|
Eksperimentell: Group 2: Reversal Procedure
This will be Group 2. Group 2 will have both the occlusion and reversal procedure. |
The occlusion system comprised of the Delivery Lumen Access Device and Vasalgel. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Study subjects achieving azoospermia
Tidsramme: Starting at the 30 day follow-up visit
|
Total number of subjects (N=40) achieving azoospermia |
Starting at the 30 day follow-up visit
|
|
Study subjects that return to baseline semen levels
Tidsramme: Correlating to Outcome 1, that follow-up timepoint at which azoospermia is reached starting at the 30 day follow-up
|
Total number of subjects (N=10) that return to baseline semen levels after reversal |
Correlating to Outcome 1, that follow-up timepoint at which azoospermia is reached starting at the 30 day follow-up
|
|
Adverse Events
Tidsramme: From the first subjects screening visit through the last subjects 14 Day phone follow up visit.
|
Rate and severity of adverse events. |
From the first subjects screening visit through the last subjects 14 Day phone follow up visit.
|
|
Subject Comfort
Tidsramme: From the first subjects occlusion visit until the last subjects 14 Day phone follow up visit.
|
Subject Comfort Assessment Scale Post Occlusion and Reversal |
From the first subjects occlusion visit until the last subjects 14 Day phone follow up visit.
|
|
Histology
Tidsramme: From the first subjects occlusion visit until the last subjects vasectomy, approximately 9 months
|
Excised portion of the vas deferens will be prepared with formalin for histological evaluation |
From the first subjects occlusion visit until the last subjects vasectomy, approximately 9 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Subject Satisfaction/Comfort Assessment
Tidsramme: From the first subjects occlusion visit until the last subjects 14 Day phone follow up visit.
|
Patient satisfaction questions along with NRS pain scale are being utilized to determine the comfort of the patient |
From the first subjects occlusion visit until the last subjects 14 Day phone follow up visit.
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Homi Zargar, MD, Western Urology
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- CIP102
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .